ライフサイエンスコーパス: vaginal discharge

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 swabs (n=392) from symptomatic females with vaginal discharge.

2 y, presenting with anomalous bleeding and/or vaginal discharge.

3 8 [1.6-2.0]), dizziness (1.7 [1.6-1.8]), and vaginal discharge (1.8 [1.7-2.0]).

4 These women were more likely to report vaginal discharge (76% versus 59%; P = 0.02) and have an

5 group had a higher rate of increased or new vaginal discharge (86.7% vs 46.0%; between-group differe

6 ymptoms, the 2 most powerful were history of vaginal discharge and history of vaginal irritation, whi

7 inical syndrome presenting with a malodorous vaginal discharge and increased vaginal pH.

8 l vaginosis (BV) is the most common cause of vaginal discharge and is associated with important publi

9 vestigated all women complaining of abnormal vaginal discharge and seeking care at maternal and child

10 ate models, vulvitis, genital ulcer disease, vaginal discharge, and Candida vaginitis were significan

11 laboratory tests, particularly microscopy of vaginal discharge, are the most useful way of diagnosing

12 Vaginal discharge as well as posterior hymenal transecti

13 ed search terms of diagnosis with vaginitis, vaginal discharge, candidiasis, bacterial vaginosis, and

14 infection but were elevated in women who had vaginal discharge, detectable HIV-1 RNA in their genital

15 he most recent sexual partner; and (c) itchy vaginal discharge in the previous 30 d, possibly indicat

16 pain (LR, 0.8; 95% CI, 0.7-0.9), history of vaginal discharge (LR, 0.3; 95% CI, 0.1-0.9), history of

17 l irritation (LR, 0.2; 95% CI, 0.1-0.9), and vaginal discharge on examination (LR, 0.7; 95% CI, 0.5-0

18 symptoms (eg, dysuria and frequency without vaginal discharge or irritation) raise the probability o

19 combination of dysuria and frequency but no vaginal discharge or irritation).

20 articularly gynecological complaints such as vaginal discharge (OR, 3.2; 95% CI, 2.2-4.8) and dyspare

21 of a symptomatic partner, dysuria, abnormal vaginal discharge, or a new sex partner during the prece

22 y, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamo

23 s receiving tamoxifen had significantly more vaginal discharge (P < .0001).

24 The presence of vaginal discharge (positive likelihood ratio, 2.7; 95% c

25 Women presenting for evaluation of vaginal discharge, STI exposure, or preventative gynecol

26 s associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal

27 present with additional symptoms, including vaginal discharge, vaginal pain/pressure, suprapubic pai

28 Self-reported itchy vaginal discharge was associated with all categories of

29 sed susceptibility to HIV acquisition, while vaginal discharge was not.

30 Syndromic STI diagnosis dependent on vaginal discharge was poorly predictive of laboratory-di

31 The incidence of new or increased vaginal discharge was significantly higher in the pessar

32 Vaginal discharge was thus a poor predictor of laborator

33 ds of condom use and increased odds of itchy vaginal discharge, which is potentially indicative of se

34 e seen for any endocrine symptoms apart from vaginal discharge, which was more pronounced with tamoxi

35 reported significantly fewer cold sweats and vaginal discharge, yet more vaginal dryness, painful int

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。